نویسندگان
1 * دانشیار، مرکز تحقیقات ارتوپدی، دانشگاه علوم پزشکی مازندران، ساری،ایران
2 **استادیار، مرکز تحقیقات ارتوپدی، دانشگاه علوم پزشکی مازندران، ساری،ایران
3 ***دستیار، گروه ارتوپدی،دانشگاه علوم پزشکی مازندران، ساری،ایران
چکیده
خلاصه
پیشزمینه: پوکی استخوان، شایعترین بیماری متابولیک استخوان است. هدف از این مطالعه بررسی تأثیر درمان ضداستئوپوروز یا داروهای بیسفسفونات و پاراتیروئید بر ترمیم استخوان در بیماران با شکستگیهای استئوپوروتیک بود.
مواد و روشها: این یک مطالعه کارآزمایی بالینی تصادفی یکسویه کورکنترل شده بود که برروی 3 گروه 20 نفره باشکستگیهای استئوپوروتیک بستری در بخش ارتوپدی بیمارستان امام خمینی (ره) و بوعلی سینای ساری طی سالهای 1395 تا 1397انجام شد: بیماران دریافتکننده هورمون پاراتیروئید)، بیماران دریافت کننده آلندرونات و بیماران گروه کنترل. کلیه بیماران در هفته 4، هفته 8 و هفته 12 جهت بررسی میزان جوشخوردگی یا رادیوگرافی ارزیابی شدند.
یافتهها:در هیچ یک از بیماران سه گروه جوشخوردگی شکستگی در 4 هفته نداشتند. زمان جوشخوردگی شکستگی افراد در 8 هفته در سه گروه درمانی سینوپار، آلندرونات و کنترل به ترتیب 20، 18 و 17 نفر بود. بیماران در تمامی گروهها در 12 هفته جوشخوردگی کامل داشتند.
نتیجهگیری: باتوجه به نتایج این مطالعه به نظر میرسد که تجویز آلندرونات و هورمون پاراتیروئید بر ترمیم شکستگیهای استئوپوروتیک دیستال رادیوس تفاوت آماری معناداری ندارند.
کلیدواژه‌ها
عنوان مقاله [English]
Anti-Osteoporosis effects of Alderonate or Parathyroid Hormone on the union of Osteoporotic Distal Radius Fractures
نویسندگان [English]
- Massoud Shayestehazar 1
- MH Karimi nasab 1
- M Razavi pour 2
- S Jour Ebrahimian 3
1 Associate professor of orthopedic research center Mazandaran university of medical sciences Sari Iran
2 Assistant professor of orthopedic research center Mazandaran university of medical sciences Sari Iran
3 Assistant of orthopedic research center Mazandaran university of medical sciences Sari Iran
چکیده [English]
Abstract
Background: Osteoporosis is the most common bone metabolic disease. The purpose of this study was to evaluate the effect of anti-osteoporosis treatment with bisphosphonate and parathyroid on bone repair in patients with osteoporosis related fractures.
Methods: This single-blind randomized controlled clinical trial was performed on three groups of 20 patients each (parathyroid hormone, alendronate and control) with osteoporosis fractures hospitalized in orthopedic ward of Emam Khomeini and Boali Sinaye Sari hospitals during 2016-2018. All the patients were assessed at the 4th, 8th, and 12th week in terms of union.
Results: While no union was reported at the end of the fourth week, 20, 18, and 17 subjects respectively on CinnoPar, alendronate and control groups had union at the end of the eighth week. Furthermore, the complete union was achieved for all patients in the 12th week.
Conclusions: According to the results of the study, no significant difference was observed in the repair of osteoporotic fractures of distal radius by alendronate and parathyroid hormone.
کلیدواژه‌ها [English]
- Keywords: Osteoporosis
- alendronate
- Parathyroid
- Radius Distal
- Black DM, Rosen CJ. Postmenopausal osteoporosis. N Engl J Med. 2016;374:254-62.
- Fischer S, Kapinos KA, Mulcahy A, Pinto L, Hayden O, Barron R. Estimating the long-term functional burden of osteoporosis-related fractures. Osteoporos Int. 2017;28:2843-51.
3.Larijani B, Resch H, BonjourJP, AghaiMeybodiHR, MohajeryTehraniMR. Osteoporosis in Iran, overview and management. Iran J Public Health. 2007;36(Supple 1):1-13.
4.Ponnapakkam T, Katikaneni R, Sakon J, Stratford R, Gensure RC. Treating osteoporosis by targeting parathyroid hormone to bone. Drug Discov Today. 2014;19:204-8.
5.Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res. 2007;22:465-75.
6.Iwamoto J, Sato Y, Takeda T, Matsumoto H. Hip fracture protection by alendronate treatment in postmenopausal women with osteoporosis: a review of the literature. ClinInterv Aging. 2008;3:483-9.
- Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, et al. Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med. 2017;377:1417-27.
- Leder BZ. Parathyroid Hormone and parathyroid hormone-related protein analogs in osteoporosis therapy. CurrOsteoporos Rep. 2017;15:110-9.
9.Lin T, Wang C, Cai XZ, Zhao X, Shi MM, Ying ZM, et al. Comparison of clinical efficacy and safety between denosumab and alendronate in postmenopausal women with osteoporosis: a meta-analysis. Int J ClinPract. 2012;66:399-408.
10.Brixen K, Chapurlat R, Cheung AM, Keaveny TM, Fuerst T, Engelke K, et al. Bone density, turnover, and estimated strength in postmenopausal women treated with odanacatib: a randomized trial. J ClinEndocrinolMetab. 2013;98:571-80.
11.Borah B, Dufresne TE, Chmielewski PA, Johnson TD, Chines A, Manhart MD. Risedronate preserves bone architecture in postmenopausal women with osteoporosis as measured by three-dimensional microcomputed tomography. Bone. 2004;34:736-46.
- Özşahin ET, Çam B, Dere F, Kürkçü M, Evrüke C, Soames R, et al. The effect of alendronate sodium on trabecular bone structure in an osteoporotic rat model. Turk J Phys Med Rehab. 2017;63(2):165-73.
13.Lewiecki EM, Adler RA, Bilezikian JP, Bouxsein ML, Marcus R, McClung MR, et al. Osteoporosis update from the 2012 Santa Fe Bone Symposium. J ClinDensitom. 2013;16:584-600.
14.Ohtori S, Orita S, Yamauchi K, Eguchi Y, Aoki Y, Nakamura J, et al. Does discontinuing teriparatide treatment and replacing it with bisphosphonate maintain the volume of the bone fusion mass after lumbar posterolateral fusion in women with postmenopausal osteoporosis? Asian Spine J. 2017;11:272-7.
- Shibamoto A, Ogawa T, Yokoyama M, Duyck J, Vandamme K, Naert I, et al. Osteogeneticeffect of low-magnitude high-frequency loading and parathyroid hormone on implant interface in osteoporosis. In Sasaki K, Suzuki O, Takahashi N, eds: Interface oral health science. Singapore;Springer; 2016.
16.Serada M, Sakurai-Tanikawa A, Igarashi M, Mitsugi K, Takano T, Shibusawa K, et al. The role of the liver and kidneys in the pharmacokinetics of subcutaneously administered teriparatide acetate in rats. Xenobiotica. 2012;42:398-407.
17.Weinstein RS, Jilka RL, Almeida M, Roberson PK, Manolagas SC. Intermittent parathyroid hormone administration counteracts the adverse effects of glucocorticoids on osteoblast and osteocyte viability, bone formation, and strength in mice. Endocrinology. 2010;151:2641-9.
18.Peichl P, Holzer LA, Maier R, Holzer G. Parathyroid hormone 1-84 accelerates fracture-healing in pubic bones of elderly osteoporotic women. J Bone Joint Surg Am. 2011;93:1583-7.
19.John MR, Widler L, Gamse R, Buhl T, Seuwen K, Breitenstein W, et al. ATF936, a novel oral calcilytic, increases bone mineral density in rats and transiently releases parathyroid hormone in humans. Bone. 2011;49:233-41.
20.Augustine M, Horwitz MJ. Parathyroid hormone and parathyroid hormone-related protein analogs as therapies for osteoporosis. CurrOsteoporos Rep. 2013;11:400-6.
21.Kraenzlin ME, Meier C. Parathyroid hormone analogues in the treatment of osteoporosis. Nat Rev Endocrinol. 2011;7:647-56.
- Cosman F, Lindsay R. Parathyroid hormone treatment for osteoporosis. In MarcusR, Feldman D, Dempster DW, Luckey M, Cauley JA, eds: Osteoporosis. Cambridge, Massachusetts; Academic Press; 2013.
- Aspenberg P, Genant HK, Johansson T, Nino AJ, See K, Krohn K, et al. Teriparatide for acceleration of fracture repair in humans: a prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures. J Bone Miner Res. 2010;25:404-14.
- Kim TY, Ha YC, Kang BJ, Lee YK, Koo KH. Does early administration of bisphosphonate affect fracture healing in patients with intertrochanteric fractures? J Bone Joint Surg Br. 2012;94:956-60.
- Aspenberg P, Johansson T. Teriparatide improves early callus formation in distal radial fractures. ActaOrthop. 2010;81:234-6.
26.Bodenner D, Redman C, Riggs A. Teriparatide in the management of osteoporosis. ClinInterv Aging. 2007;2:499-507.
- Orwoll ES, Scheele WH, Paul S, Adami S, Syversen U, Diez-Perez A, et al. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res. 2003;18:9-17.
- Hawley S, Leal J, Delmestri A, Prieto-Alhambra D, Arden NK, Cooper C, et al. Anti-osteoporosis medication prescriptions and incidence of subsequent fracture among primary hip fracture patients in England and Wales: An interrupted time-series analysis. J Bone Miner Res. 2016;31:2008-15.
)